0000000000419845

AUTHOR

Mario Legarda

0000-0003-1058-9042

showing 2 related works from this author

Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentr…

2019

Correspondence.

MaleOncologymedicine.medical_specialtymedicine.medical_treatmentDisease-Free SurvivalRecurrenceRenal DialysisMultiple myelomaDaratumumabInternal medicinemedicineHumansIn patientSingle agentRelapseDialysisMultiple myelomaAgedRetrospective Studiesrelapsebusiness.industryAntibodies MonoclonalDaratumumabRefractory Multiple MyelomaHematologyMiddle Ageddaratumumabmedicine.diseasemultiple myelomaSurvival RatedialysisFemalebusinessDialysisBritish Journal of Haematology
researchProduct

Recent Advances in the Treatment of Patients with Multiple Myeloma

2020

Simple Summary The evolving data from trials assessing novel combinations as a part of the frontline and relapse treatment in transplant and non-transplant candidates have markedly improved the anti-myeloma efficacy of the different therapeutic regimens and improved patients’ prognosis. Current treatment objectives are focused to further improve the rate of complete remission, time to progression, progression-free survival and overall survival without increasing toxicity. Besides, different strategies are being developed in the elderly population as this group of patients requires a closer monitoring with individualized, dose-modified regimens to improve tolerability while maintaining their…

Cancer Researchmedicine.medical_specialtyautologous stem cell transplantationmedicine.medical_treatmentHematopoietic stem cell transplantationDiseaseNewly diagnosedReviewlcsh:RC254-282maintenance03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationmedicinecar-t cellsIntensive care medicineMultiple myelomanovel drugsbusiness.industryrelapsed refractory multiple myelomaearly relapseAdvanced stageImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensClinical trialmultiple myelomalate relapseOncology030220 oncology & carcinogenesisimmunotherapybusinessconsolidation030215 immunologyCancers
researchProduct